February 22, 2022
Professor Ashok Venkitaraman is the Director of the Cancer Science Institute of Singapore, and a Distinguished Professor of Medicine at NUS Yong Loo Lin School of Medicine, a member of the National University Health System (NUHS). He holds a joint appointment at the Agency for Science, Technology and Research (A*STAR).
Prof Venkitaraman’s research has contributed fundamentally to our understanding of how cancer is suppressed by genes that maintain the integrity of DNA in the human genome. His laboratory is recognized for the discovery that mutations in the breast and ovarian cancer gene, BRCA2, provoke genome instability leading to carcinogenesis. Prof Venkitaraman now seeks to achieve a deeper understanding of the steps that underlie carcinogenesis, in order to find new strategies to intercept cancer development well before the disease reaches an advanced and hard-to- treat stage. He has developed new technologies to target previously ‘undruggable’ targets, and is a serial biotech entrepreneur, most recently as a founder of PhoreMost Ltd.
Prof. Venkitaraman has been elected a Fellow of the Academy of Medical Sciences, London, and as a member of EMBO.
A new national consortium – the Consortium for Clinical Research and Innovation, Singapore (CRIS) – has been officially launched by the Minister for Health Mr Ong Ye Kung on 6 April 2022 CRIS brings together five key national R&D, clinical translation and service initiatives that will advance clinical research and innovation for Singapore, and establish important capabilities for a future-ready healthcare system
Delfi Diagnostics’ liquid biopsy test uses machine learning to spot changes in patients’ DNA fragmentation profiles that indicate the presence of cancerous cells.